Synopsis:
Emcure Pharmaceuticals and Sanofi India have partnered for exclusive distribution and promotion of Sanofi’s oral anti-diabetic products in India, aiming to expand patients’ access while Sanofi continues manufacturing.
During Thursday’s trading session, shares of a leading Indian pharma company, which develops, manufactures, and globally markets a broad range of pharmaceutical products, surged nearly 2.3 percent on BSE after the company entered into a partnership with Sanofi India.
At 10:45 a.m., the shares of Emcure Pharmaceuticals Limited were trading in the green at Rs. 1,371.55 on BSE, up by around 0.6 percent, as against its previous closing price of Rs. 1,363.85, with a market cap of Rs. 25,992 crores. The stock has delivered negative returns of more than 6 percent YTD, but has gained by nearly 3.4 percent in the last one month.
What’s the News
Emcure Pharmaceuticals Limited and Sanofi India Limited (SIL) have entered into an exclusive agreement for the distribution and promotion of Sanofi’s oral anti-diabetic (OAD) products in India, effective immediately.
Under this agreement, Emcure will exclusively distribute and promote Sanofi’s OAD range of products, which includes well-established brands like Amaryl and Cetapin.
While SIL will continue to own and manufacture these brands across Sanofi’s plants in India and internationally, Emcure will leverage its strengths to engage healthcare professionals and expand the reach of these therapeutic solutions for patients who need them across the country.
Sanofi India Limited (SIL), a publicly listed pharma company with a market cap of about Rs. 13,678 crores, is engaged in the manufacturing and trading of drugs and pharmaceutical products, with its manufacturing facility at Goa. It has various independent contract/third-party manufacturers based across India, and sells its products through independent distributors primarily in India.
Financials and More
In Q4 FY25, Emcure Pharma reported a significant rise in revenue from operations by around 19 percent YoY to Rs. 2,116 crores, from Rs. 1,771 crores in Q4 FY24. Likewise, the net profit increased from Rs. 121 crores to Rs. 197 crores, representing a nearly 63 percent YoY growth over the same period.
As per the July 2024 shareholding pattern on BSE, promoter Namita Vikas Thapar holds a 2.68 percent stake in the company. She is the Executive Director of Emcure Pharma, one of seven sharks on Shark Tank India, and is widely known as one of India’s leading businesswomen.
Emcure Pharmaceuticals Limited is a global leader in pharmaceuticals and is ranked as the 12th largest pharma company in India in terms of Domestic Sales for MAT June 2024. Emcure is present in 70+ countries globally, including Europe and Canada.
The company is engaged in developing, manufacturing, and globally marketing a broad range of pharmaceutical and biopharmaceutical products of dosage forms, including oral solids, oral liquids, injectables, including lipid, liposomal, lyophilised injectables, biologics, vaccines and complex APIs, including chiral molecules and cytotoxic products.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
